Welcome to Vimpat. This site is screen reader friendly.

Skip to content Skip to main navigation Skip to footer navigation

The First Novel Mechanism of Action in Almost 10 Years

The following video details how Vimpat targets seizures.

Vimpat works differently by selectively enhancing slow inactivation of the sodium channels.¹

Photo: Describes how Vimpat is effective and the typical drug is not

Selective enhancement of slow inactivation with Vimpat¹:

Enhances the number of sodium channels entering into the slow inactivated state
Targets activity occurring during sustained high-frequency neuronal firing or prolonged depolarization, as seen in epilepsy
Regulates and reduces the long-term availability of sodium channels
Does not affect activity mediated by fast inactivation

The precise mechanism by which lacosamide exerts its antiepileptic effect in humans remains to be fully elucidated.

Reference

Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Reviews. 2007;13(1):21-42.

IMPORTANT SAFETY INFORMATION

VIMPAT^® tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older.
VIMPAT injection is indicated as short-term replacement when oral administration is temporarily not feasible in these patients. Patients should be advised that VIMPAT may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, VIMPAT should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with VIMPAT should be discontinued.

AEDs increase the risk of suicidal behavior and ideation. Patients taking VIMPAT should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

The most common adverse reactions occurring in ≥10 percent of VIMPAT-treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia.

Please see VIMPAT Prescribing Information.